Clinical Trials

Key Inclusion Criteria:

1. Adult ≥18 years old, able to provide informed consent
2. Clinical diagnosis of LMNA-related dilated cardiomyopathy (DCM) with LV systolic dysfunction
3. Pathogenic or likely pathogenic LMNA mutation confirmed by a CLIA-certified/CAP-accredited laboratory
4. NYHA Functional Class I, II, or III
5. LVEF >25% and ≤45% by echocardiography
6. Implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator )CRT-D) implanted >3 months prior to consent

Key Exclusion Criteria:

1. Any chronic medical condition that, in the Investigator's opinion, would compromise participant safety or compliance
2. Hospitalization as an inpatient for the following conditions within 3 months prior to signing the ICF: Heart failure, Persistent/refractory ventricular arrhythmia requiring external defibrillation, or multiple/recurrent cardioversion/defibrillation by ICD Indication for, or history of, LV assist device or cardiac transplantation due to end-stage cardiac dysfunction
3. Current or anticipated need for chronic IV inotropic therapy

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 08/11/2026. Questions regarding updates should be directed to the study team contact.